This Perspective examines Thailand's role in cell and gene therapy, focusing on regulatory development and early clinical experience. These therapies are used in Thailand for β-thalassemia, or blood cancer, together with the evolving ATMP regulatory framework and the ATMP Sandbox Project. Rather than cataloguing global indications, we analyze how selected advances intersect with Thailand's health system, highlighting opportunities and constraints for its role as a regional site for ATMP research, manufacturing, and access in Southeast Asia.
Viprakasit et al. (Wed,) studied this question.